CAS: 1450833-55-2; ((1R,2R,3S,4R)-2,3-Dihydroxy-4-((2-(3-((Trifluoromethyl)Thio)Phenyl)Pyrazolo[1,5-A]Pyrimidin-7-yl)Amino)Cyclopentyl)Methyl Sulfamate

主要参考文献

1. Preparation of ubiquitin-​activating enzyme inhibitor and use alone and in combination with other chemotherapeutic agents for treatment of cancer by Bence, Neil; Huck, Jessica; Hyer, Marc; Milhollen, Michael; Shi, Judy Qiuju; Traore, Tary from PCT Int. Appl. (2016), WO 2016069392 A1 20160506. | Language: English, Database: CAPLUS 2. Preparation of ubiquitin-​activating enzyme inhibitor and use in combination with radiation for treatment of cancer by Bence, Neil; Hyer, Marc; Milhollen, Michael; Samnotra, Vivek; Santillana Soto, Sergio Luis; Sappal, Darshan from PCT Int. Appl. (2016), WO 2016069393 A1 20160506. | Language: English, Database: CAPLUS 3. Preparation of pyrazolopyrimidinyl compounds as inhibitors of ubiquitin-​activating enzyme by Afroze, Roushan; Bharathan, Indu T.; Ciavarri, Jeffrey P.; Fleming, Paul E.; Gaulin, Jeffrey L.; Girard, Mario; Langston, Steven P.; Soucy, Francois R.; Wong, Tzu-Tshin; Ye, Yingchun from PCT Int. Appl. (2013), WO 2013123169 A1 20130822. | Language: English, Database: CAPLUS

合成参考文献

参考文献:10.1074/jbc.ra119.009147
摘要:Sha Z, Blyszcz T, González-Prieto R, Vertegaal ACO, Goldberg AL. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. Journal of Biological Chemistry. 2019 Oct;294(42):15218–34. doi: 10.1074/jbc.ra119.009147.